Trial · NCT03910803
Treatment of Moderate Hidradenitis Suppurativa
NCT03910803, Phase 2, Unknown, Florida Academic Dermatology Centers
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Moderate Hidradenitis Suppurativa. Trials, record NCT03910803. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03910803
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Moderate Hidradenitis Suppurativa
- NCT number
- NCT03910803
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Florida Academic Dermatology Centers
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Brodalumab
- First posted
- 2019-04-10
- Last updated
- 2019-04-10
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hidradenitis Suppurativa Clinical Response (HiSCR) | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | Patients at week 16 achieving the Hidradenitis Suppurativa Clinical Response (HiSCR), defined as a ≥ 30% reduction in the total number of abscess and inflammatory nodules, with no increase in the number of abscesses or draining fistulas. |
| Primary | Hidradenitis Suppurativa Clinical Response (HiSCR30) | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | Patients at week 16 achieving the Hidradenitis Suppurativa Clinical Response (HiSCR), defined as a ≥ 30% reduction in the total number of abscess and inflammatory nodules, with no increase in the number of abscesses or draining fistulas. (HiSCR30) when compared with baseline. |
| Primary | Hidradenitis Suppurativa Clinical Response (HiSCR50) | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | Patients achieving a ≥ 30% and ≥ 50% reduction in HiSCR at week 24; |
| Secondary | Physician s Global Assessment ( PGA) | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | The PGA score is based on a cumulative global assessment of nodule, abscess, and fistula counts corresponding to a 5-point score (0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe). Efficacy endpoint : the proportions of patients achieving a 1-point reduction in the PGA score. |
| Secondary | Modified Sartorius | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | The modified Sartorius score consists of 4 clinical parameters including the number of affected areas and HS lesion hallmarks. It has a minimum value of 0 and no maximum limit.8 Efficacy endpoint :Changes in Modified Sartorius scale from Baseline to Week 16 |
| Secondary | VAS | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | Pain will be assessed using a 100-mm VAS (0 = no pain, 100 = maximum pain). The number of patients achieving a two point reduction (required from baseline score) in VAS pain score at week 16 |
| Secondary | Dermatology Life Quality Index or DLQI | Study assessments occurr at baseline and at weeks 4, 8, 12, 16, 20, 24, and 28" | It is a validated and widely used questionnaire for assessing Quality of Life related to dermatology conditions. Its score constitutes the summation of responses to all 10 items, ranging from 0 (the best QoL) to 30 (worse QoL). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03910803
GET https://conductscience.org/api/trials/v1/NCT03910803/registered